Infantile Hemangioma (IH) is the most common benign tumor in early childhood, with a prevalence of ~5% in infants, more female patients than male patients (with a male : female ratio of 1:3 to 1:5), with approximately 60% occurring in the head and neck. Hemangiomas often grow rapidly after birth and slowly regress after a stable period. However, after regression, local redness, pigment changes, capillary dilation, atrophic scars, and fibrous adipose tissue growths often remain, which to varying degrees affect aesthetics. Hemangioma not only affects the appearance and physiological function of the human body, but also brings huge mental pressure and even psychological disorders to patients due to its deformity and appearance defects. In addition, some lesions are life-threatening due to ulcers, infections, bleeding, high flow shunting heart failure, or special site conditions, causing pain to patients and their families. Furthermore, about 10% of hemangiomas grow rapidly, and if not actively treated, various complications can occur, such as respiratory obstruction, affecting vision, ulceration, infection, bleeding, affecting aesthetics, and even endangering life in a few cases. Therefore, infant hemangiomas require active treatment.

In the past, various methods have been used for the treatment of infantile hemangioma, including oral or injection drug therapy (hormones, vincristine, α Interferon, Pingyangmycin), laser therapy, radioactive nuclide application or local injection, cryotherapy, surgical treatment, etc. They have varying therapeutic effects, multiple and serious side effects or complications, which limit their clinical promotion and use in the treatment of infantile hemangioma. The currently marketed drug for proliferative infantile hemangioma is oral propranolol solution, which is a non-selective β Adrenergic receptor blocker. The application of oral propranolol solution is a revolutionary milestone in the treatment of vascular tumors, but it has certain systemic adverse reactions and is not suitable for small and superficial lesions. Therefore, there is an urgent need to develop a safe drug suitable for the treatment of superficial infantile hemangioma.